| Description | |
|---|---|
| Catalogue Number | 14-570 |
| Brand Family | Upstate |
| Trade Name |
|
| Description | Ret Protein, active, 10 µg |
| Overview | N-Terminal GST-tagged, recombinant, human Ret amino acids 658-end |
| Product Information | |
|---|---|
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Active, N-Terminal GST-tagged, recombinant, human Ret amino acids 658-end, for use in Kinase Assays. |
| Key Applications |
|
| Biological Information | |
|---|---|
| Source | expressed by baculovirus in Sf21 insect cells |
| Specific Activity | For Specific Activity data, refer to the Certificate of Analysis for individual lots of this enzyme. |
| Entrez Gene Number |
|
| Entrez Gene Summary | This gene, a member of the cadherin superfamily, encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This gene plays a crucial role in neural crest development, and it can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations in this gene are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma. Two transcript variants encoding different isoforms have been found for this gene. Additional transcript variants have been described but their biological validity has not been confirmed. |
| Gene Symbol |
|
| Protein Target | Ret |
| Purification Method | Glutathione agarose affinity chromatography |
| Target Sub-Family | TK |
| UniProt Number |
|
| UniProt Summary | FUNCTION: SwissProt: P07949 # Probable receptor with tyrosine-protein kinase activity; important for development. SIZE: 1114 amino acids; 124319 Da SUBUNIT: Phosphorylated form interacts with the PBT domain of DOK2, DOK4 and DOK5 (By similarity). SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein. PTM: Phosphorylated. & Autophosphorylated on C-terminal tyrosine residues upon ligand stimulation. DISEASE: SwissProt: P07949 # Defects in RET are a cause of pheochromocytoma [MIM:171300]. The pheochromocytomas are catecholamine-producing, chromaffin tumors that arise in the adrenal medulla in 90% of cases. In the remaining 10% of cases, they develop in extra- adrenal sympathetic ganglia and may be referred to as paraganglioma. Pheochromocytoma usually presents with hypertension. Approximately 10% of pheochromocytoma is hereditary. The genetic basis for most cases of non-syndromic familial pheochromocytoma is unknown. & Defects in RET are the cause of medullary thyroid carcinoma (MTC) [MIM:155240]. MTC is a rare tumor derived from the C cells of the thyroid. Three hereditary forms are known, that are transmitted in an autosomal dominant fashion: (a) multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of MTC cases and where MTC is the only clinical manifestation. & Defects in RET are the cause of multiple neoplasia type IIA (MEN2A) [MIM:171400]; also called multiple neoplasia type II (MEN2). MEN2A, the most frequent form of MTC, is an inherited cancer syndrome characterized by MTC, phaeochromocytoma and/or hyperparathyroidism. & Defects in RET are the cause of multiple neoplasia type IIB (MEN2B) [MIM:162300]. MEN2B is an uncommon inherited cancer syndrome characterized by predisposition to MTC and phaeochromocytoma which is associated with marfanoid habitus, mucosal neuromas, skeletal and ophtalmic abnormalities, and ganglioneuromas of the intestine tract. Then the disease progresses rapidly with the development of metastatic MTC and a pheochromocytome in 50% of cases. & Defects in RET are a cause of Hirschsprung disease (HSCR) [MIM:142623]. HSCR is a genetic disorder of neural crest development characterized by the absence of intramural ganglion cells in the hindgut, often resulting in intestinal obstruction. Occasionally, MEN2A or FMTC occur in association with HSCR. & Chromosomal aberrations involving RET are a cause of thyroid papillary carcinoma (PACT) [MIM:188550]. Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene; inversion inv(10)(q11.2;q11.2) generates the RET/NCOA4 (PTC3) oncogene; translocation t(10;14)(q11;q32) with GOLGA5 generates the RET/GOLGA5 (PTC5) oncogene; translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET fusion; translocation t(6;10)(p21.3;q11.2) with RFP generates the Delta RFP/RET oncogene; translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET (PTC7) oncogene; translocation t(7;10)(q32;q11) with TIF1 generates the TIF1/RET (PTC6) oncogene. The PTC5 oncogene has been found in 2 cases of PACT in children exposed to radioactive fallout after Chernobyl. & Defects in RET are a cause of congenital central hypoventilation syndrome (CCHS) [MIM:209880]; also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia. & Defects in RET may be a cause of colorectal cancer (CRC) [MIM:114500]. SIMILARITY: SwissProt: P07949 ## Belongs to the protein kinase superfamily. Tyr protein kinase family. & Contains 1 cadherin domain. & Contains 1 protein kinase domain. |
| Molecular Weight | 79.2kDa |
| Product Usage Statements | |
|---|---|
| Quality Assurance | routinely evaluated by phosphorylation of IFG-1Rtide |
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | 6 months at -70°C |
| Packaging Information | |
|---|---|
| Material Size | 10 µg |
| Material Package | Also available in 250 µg size --call for pricing and availability and reference catalog number 14-570M when ordering the 250 µg size. |